{
  "@context": {
    "dcterms": "http://purl.org/dc/terms/",
    "cito": "http://purl.org/spar/cito/",
    "deo": "http://purl.org/spar/deo/"
  },
  "@id": "https://hypothesis.bioagent.ai/xc47uk8wate",
  "@type": "deo:FutureWork",
  "cito:usesDataFrom": [
    "https://doi.org/10.1186/s13041-024-01028-8",
    "https://doi.org/10.1038/ncomms14207",
    "https://doi.org/10.1002/dad2.12391",
    "https://doi.org/10.1038/s41586-023-06621-4"
  ],
  "dcterms:references": [
    "# Mechanistic Hypothesis Connecting DOPAL's Anti-Amyloid Effects with Selective VTA Dopaminergic Neuron Apoptosis\n\n## 1. Background\nDOPAL (3,4-dihydroxyphenylacetaldehyde), a reactive intermediate in dopamine metabolism produced by monoamine oxidase (MAO), demonstrates neuroprotective properties by decreasing Aβ oligomerization in human neuroblastoma cells, thereby reducing Aβ-mediated cytotoxicity. In Alzheimer's disease models, ventral tegmental area (VTA) dopaminergic neurons exhibit selective vulnerability to apoptosis during pre-plaque stages, contrasting with dopaminergic neurons in other regions like the substantia nigra pars compacta, which are primarily affected in Parkinson's disease. L-DOPA administration significantly reduces Aβ plaque burden by upregulating amyloid-degrading enzymes NEP and ADAM17, suggesting complex interactions between dopamine metabolism and amyloid processing.\n\n## 2. Knowledge Gap\nThe paradoxical relationship between DOPAL's protective effects against Aβ oligomerization and the selective vulnerability of VTA dopaminergic neurons to apoptosis remains unexplained. Specifically, it is unclear why neurons producing a potentially protective compound (DOPAL) would be particularly susceptible to degeneration in early Alzheimer's disease.\n\n## 3. Central Hypothesis\nDOPAL establishes a hormetic response curve in VTA dopaminergic neurons wherein moderate levels inhibit Aβ oligomerization through direct chemical interaction, while chronic production leads to mitochondrial dysfunction through BAX/BAK pore formation, triggering apoptosis specifically in VTA neurons due to their distinct bioenergetic profile.\n\n## 4. Proposed Mechanism\n1. At physiological concentrations, DOPAL binds to hydrophobic regions of Aβ monomers through its reactive aldehyde group, inducing conformational changes that prevent β-sheet formation and subsequent oligomerization, thereby reducing Aβ cytotoxicity.\n\n2. VTA dopaminergic neurons, unlike other dopaminergic populations, exhibit higher baseline dopamine turnover and lower aldehyde dehydrogenase (ALDH) activity, resulting in greater DOPAL accumulation within these specific neurons.\n\n3. Chronic exposure to Aβ in early AD increases oxidative stress in VTA neurons, leading to decreased ALDH activity and further DOPAL accumulation, exceeding the hormetic threshold.\n\n4. Accumulated DOPAL promotes BAX/BAK translocation to the outer mitochondrial membrane, inducing minority MOMP (mitochondrial outer membrane permeabilization) and causing cytosolic release of mitochondrial DNA (mtDNA).\n\n5. The released mtDNA activates the cGAS-STING pathway, initiating an inflammatory response and ultimately triggering apoptotic pathways specifically in these vulnerable VTA neurons, despite their initial protective DOPAL-mediated anti-oligomerization mechanism.\n\n## 5. Testable Predictions\n1. Ex vivo analysis of VTA versus substantia nigra neurons should reveal higher DOPAL/DOPAC ratios in VTA neurons, reflecting lower ALDH activity, with this difference exacerbated in AD models compared to controls.\n\n2. Selective upregulation of ALDH2 (the primary enzyme metabolizing DOPAL) specifically in VTA neurons of AD model mice should protect against dopaminergic neurodegeneration and delay hippocampal-dependent memory deficits without affecting DOPAL's anti-oligomerization effects on Aβ.\n\n3. Brain samples from AD patients should show a biphasic correlation between DOPAL levels and apoptotic markers in VTA regions: initially negative correlation at low DOPAL concentrations (reflecting protection) but positive correlation at higher concentrations (reflecting toxicity).\n\n## 6. Potential Experimental Approaches\n1. Generate a transgenic mouse model expressing a fluorescent DOPAL biosensor coupled with mitochondrial markers in dopaminergic neurons, crossed with AD model mice. This would allow real-time visualization of DOPAL levels, mitochondrial integrity, and apoptotic events in different dopaminergic populations using two-photon microscopy in intact circuits or slice preparations.\n\n2. Develop an in vitro system using induced pluripotent stem cells (iPSCs) differentiated into VTA-like and substantia nigra-like dopaminergic neurons from AD patients and controls. Compare their DOPAL metabolism, response to synthetic Aβ, mitochondrial function, and susceptibility to apoptosis when treated with varying concentrations of DOPAL or modulators of ALDH activity, assessing both Aβ oligomerization status and cell viability endpoints.\n\nThis hypothesis provides a novel framework explaining how the same molecule (DOPAL) could simultaneously protect against Aβ toxicity while contributing to selective vulnerability of VTA neurons, integrating dopamine metabolism, mitochondrial function, and inflammation in the pathogenesis of early Alzheimer's disease."
  ],
  "dcterms:subject": [
    "amyloid beta",
    "apoptosis"
  ],
  "dcterms:source": [
    "DOPAL, a dopamine metabolite, decreases Aβ oligomerization in human neuroblastoma cells, reducing the cytotoxic effects of Aβ.",
    "Apoptotic cell death is a component of the neurodegeneration process observed in VTA dopaminergic neurons."
  ],
  "dcterms:abstract": [
    "Dopamine plays important roles in cognitive function and inflammation and therefore is involved in the pathogenesis of neurodegenerative diseases, including Alzheimer's disease (AD). Drugs that increase or maintain dopamine levels in the brain could be a therapeutic strategy for AD. However, the effects of dopamine and its precursor levodopa (L‑DOPA) on Aβ/tau pathology in vivo and the underlying molecular mechanisms have not been studied in detail. Here, we investigated whether L‑DOPA treatment alters neuroinflammation, Aβ pathology, and tau phosphorylation in 5xFAD mice, a model of AD. We found that L‑DOPA administration significantly reduced microgliosis and astrogliosis in 5xFAD mice. In addition, L‑DOPA treatment significantly decreased Aβ plaque number by upregulating NEP and ADAM17 levels in 5xFAD mice. However, L‑DOPA‑treated 5xFAD mice did not exhibit changes in tau hyperphos‑phorylation or tau kinase levels. These data suggest that L‑DOPA alleviates neuroinflammatory responses and Aβ pathology but not tau pathology in this mouse model of AD.",
    "The study examines dopaminergic neuron loss in Alzheimers disease focusing on the ventral tegmental area VTA in Tg2576 mice The research demonstrates selective loss of dopaminergic neurons specifically in the VTA during pre plaque stages contrasting with Parkinsons disease where neurons are lost in the substantia nigra pars compacta but preserved in VTA Apoptotic cell death contributes to VTA dopaminergic neuron degeneration affecting dopamine release in the hippocampus and impacting synaptic plasticity particularly in the hippocampal CA1 region Reduced dopamine outflow in Tg2576 mice leads to memory deficits and impaired reward processing while noradrenaline outflow remains unchanged indicating preserved noradrenergic projections from the locus coeruleus The study investigated several treatments Levodopa L DOPA administration successfully rescued multiple deficits including CA1 synaptic plasticity dendritic spine density hippocampal post synaptic density composition memory function and food reward processing L DOPA was administered at 10 mg kg along with benserazide at 12 mg kg Similarly selegiline a monoamine oxidase B inhibitor improved dopamine outflow in the hippocampus restored synaptic plasticity dendritic spine density memory performance and reward processing The treatment also restored D1 receptors and GluA1 expression in hippocampal PSD fractions These findings establish a clear link between dopamine signaling memory formation and reward processing in Alzheimers disease with dopaminergic dysfunction occurring at early stages The research suggests potential therapeutic approaches through dopamine system modulation using established drugs like L DOPA and selegiline",
    "[18F]AZD4694 is an amyloid beta (Aβ) imaging agent used in several observational studies and clinical trials. This study assessed 146 individuals evaluated with [18F]AZD4694 at baseline and a 2‐year follow‐up, revealing longitudinal patterns of Aβ accumulation. Results showed that cognitively unimpaired older adults displayed subtle Aβ accumulation, while Aβ positive cases exhibited greater increases, underscoring the agent’s potential to monitor Aβ levels in clinical settings.",
    "Senescent cells drive age-related tissue dysfunction partially through the induction of a chronic senescence-associated secretory phenotype (SASP). Mitochondria are major regulators of the SASP; however, the underlying mechanisms have not been elucidated. Here we find that mitochondrial outer membrane permeabilization (MOMP) occurring in a subset of mitochondria is a feature of cellular senescence. This process, called minority MOMP (miMOMP), requires BAX and BAK macropores enabling the release of mitochondrial DNA (mtDNA) into the cytosol. Cytosolic mtDNA in turn activates the cGAS–STING pathway, a major regulator of the SASP..."
  ]
}